The Race Oncology Annual General Meeting was held on Monday 27 November 2023. During the meeting the Race Board and management team provided an update on the forward-looking strategy, detailed new clinical development plans and explained why we remain extremely positive about our ability to capitalise on bisantrene’s full potential, and ultimately deliver outcomes for patients and shareholders.

A recorded version is available to watch by clicking below.